Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 9/20 | 0.41 |
| ▸ | UBE2M | P61081 | 8/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019198 | 0.86 | SMN1; SMN2 (0.38) | DCUN1D1UBE2MACKR3KMT2AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL1017954 | 0.83 | SLC2A1 (0.42) | DCUN1D1UBE2MACKR3KMT2ADRD2 | |
| Trifluoroacetic Acid SCHEMBL1017952 | 0.83 | SLC2A1 (0.42) | DCUN1D1UBE2MACKR3KMT2ADRD2 | |
| SCHEMBL12955051 | 0.82 | ACKR3 (0.42) | DCUN1D1UBE2MACKR3KMT2ADRD2 | |
| SCHEMBL13663359 | 0.79 | KMT2A (0.41) | DCUN1D1UBE2MACKR3KMT2ADRD2 | |
| SCHEMBL1016970 | 0.77 | MAPT (0.46) | KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL1020249 | 0.77 | PRKAB2 (0.46) | ACKR3KMT2ASIGMAR1 | |
| SCHEMBL1018639 | 0.76 | PRKAB2 (0.46) | KMT2AALDH1A1SIGMAR1EPHX2 | |
| SCHEMBL1018993 | 0.70 | DCUN1D1 (0.47) | DCUN1D1UBE2MACKR3KMT2ADRD2 | |
| SCHEMBL2474532 | 0.70 | UBE2M (0.53) | DCUN1D1UBE2MACKR3KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | DCUN1D1 4520/4885UBE2M 1792/4885ACKR3 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.